These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

58 related items for PubMed ID: 9022806

  • 1. Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties.
    Lin NH, Gunn DE, Ryther KB, Garvey DS, Donnelly-Roberts DL, Decker MW, Brioni JD, Buckley MJ, Rodrigues AD, Marsh KG, Anderson DJ, Buccafusco JJ, Prendergast MA, Sullivan JP, Williams M, Arneric SP, Holladay MW.
    J Med Chem; 1997 Jan 31; 40(3):385-90. PubMed ID: 9022806
    [Abstract] [Full Text] [Related]

  • 2. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.
    Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes ML, Cadman ED, Adams P, Garvey DS.
    J Pharmacol Exp Ther; 1994 Jul 31; 270(1):310-8. PubMed ID: 7518514
    [Abstract] [Full Text] [Related]

  • 3. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
    Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT.
    J Pharmacol Exp Ther; 1994 Jul 31; 270(1):319-28. PubMed ID: 7913497
    [Abstract] [Full Text] [Related]

  • 4. Characterization of [3H]ABT-418: a novel cholinergic channel ligand.
    Anderson DJ, Williams M, Pauly JR, Raszkiewicz JL, Campbell JE, Rotert G, Surber B, Thomas SB, Wasicak J, Arneric SP.
    J Pharmacol Exp Ther; 1995 Jun 31; 273(3):1434-41. PubMed ID: 7791118
    [Abstract] [Full Text] [Related]

  • 5. Novel isoxazoles which interact with brain cholinergic channel receptors have intrinsic cognitive enhancing and anxiolytic activities.
    Garvey DS, Wasicak JT, Decker MW, Brioni JD, Buckley MJ, Sullivan JP, Carrera GM, Holladay MW, Arneric SP, Williams M.
    J Med Chem; 1994 Apr 15; 37(8):1055-9. PubMed ID: 7909335
    [No Abstract] [Full Text] [Related]

  • 6. Anxiolytic-like effects of the novel cholinergic channel activator ABT-418.
    Brioni JD, O'Neill AB, Kim DJ, Buckley MJ, Decker MW, Arneric SP.
    J Pharmacol Exp Ther; 1994 Oct 15; 271(1):353-61. PubMed ID: 7965735
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties.
    Arneric SP, Sullivan JP, Decker MW, Brioni JD, Bannon AW, Briggs CA, Donnelly-Roberts D, Radek RJ, Marsh KC, Kyncl J.
    Alzheimer Dis Assoc Disord; 1995 Oct 15; 9 Suppl 2():50-61. PubMed ID: 8534424
    [Abstract] [Full Text] [Related]

  • 10. In vitro evaluation of 11C-labeled (S)-nicotine, (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole, and (R,S)-1-methyl-2-(3-pyridyl)azetidine as nicotinic receptor ligands for positron emission tomography studies.
    Sihver W, Fasth KJ, Ogren M, Bivehed H, Bergström M, Nordberg A, Watanabe Y, Långström B.
    J Neurochem; 1998 Oct 15; 71(4):1750-60. PubMed ID: 9751211
    [Abstract] [Full Text] [Related]

  • 11. Regulation of human alpha4beta2 neuronal nicotinic acetylcholine receptors by cholinergic channel ligands and second messenger pathways.
    Gopalakrishnan M, Molinari EJ, Sullivan JP.
    Mol Pharmacol; 1997 Sep 15; 52(3):524-34. PubMed ID: 9281615
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.
    Holladay MW, Wasicak JT, Lin NH, He Y, Ryther KB, Bannon AW, Buckley MJ, Kim DJ, Decker MW, Anderson DJ, Campbell JE, Kuntzweiler TA, Donnelly-Roberts DL, Piattoni-Kaplan M, Briggs CA, Williams M, Arneric SP.
    J Med Chem; 1998 Feb 12; 41(4):407-12. PubMed ID: 9484491
    [Abstract] [Full Text] [Related]

  • 14. Potential nicotinic acetylcholine receptor ligands from 2,4-methanoproline derivatives.
    Patel AB, Malpass JR.
    J Med Chem; 2008 Nov 13; 51(21):7005-9. PubMed ID: 18841955
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice.
    Damaj MI, Fei-Yin M, Dukat M, Glassco W, Glennon RA, Martin BR.
    J Pharmacol Exp Ther; 1998 Mar 13; 284(3):1058-65. PubMed ID: 9495867
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CR 2945: a novel CCKB receptor antagonist with anxiolytic-like activity.
    Revel L, Mennuni L, Garofalo P, Makovec F.
    Behav Pharmacol; 1998 May 13; 9(3):183-94. PubMed ID: 9832933
    [Abstract] [Full Text] [Related]

  • 20. 2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.
    Huang D, Poon SF, Chapman DF, Chung J, Cramer M, Reger TS, Roppe JR, Tehrani L, Cosford ND, Smith ND.
    Bioorg Med Chem Lett; 2004 Nov 15; 14(22):5473-6. PubMed ID: 15482906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.